The newsletter for doctors
May 10, 2022
Issue 3 of the Endo Nutshell Series involves the clinical benefits of dapagliflozin. The first part of this issue involves a clinical analysis, which inferred that treatment with dapagliflozin can successfully reduce the risk of new-onset of type 2 diabetes in patients with chronic kidney disease and heart failure.
The next part involves a global update on the association of HbA1c with cardiovascular and renal outcomes as well as the beneficial effects of dapagliflozin. Another part involves the technological update of the allograft system for the management of diabetic foot ulcers.
Finally, the issue concludes with the conference on European Congress of Endocrinology 2021 (Online), which will be held on May 22nd-26th, 2021. Mahapatra H et al. inferred that dapagliflozin may be beneficial in improving transaminitis in diabetic patients with non-alcoholic fatty liver disease.
Nutshell | The newslettter for doctors